IN THE SPOTLIGHT

Tailoring ROS1+ NSCLC Treatment: The Role of Biomarker Testing

Tailoring ROS1+ NSCLC Treatment: The Role of Biomarker Testing

Navigating the Treatment Landscape for ROS1+ NSCLC

Navigating the Treatment Landscape for ROS1+ NSCLC

Dr Girard on Findings From the LUMINOSITY Trial in c-Met–Overexpressing NSCLC

Dr Girard on Findings From the LUMINOSITY Trial in c-Met–Overexpressing NSCLC

A Case of Metastatic ROS1 Fusion-Positive NSCLC

A Case of Metastatic ROS1 Fusion-Positive NSCLC

Oncology expert reveals the impact of biomarker testing on the outcomes of targeted therapies for cancer

Oncology expert reveals the impact of biomarker testing on the outcomes of targeted therapies for cancer

Taletrectinib Extends Cancer-Free Time With Fewer Neurological Side Effects in NSCLC Patients

Taletrectinib Extends Cancer-Free Time With Fewer Neurological Side Effects in NSCLC Patients

Encorafenib Plus Binimetinib Shows ‘Prolonged Efficacy’ in Metastatic NSCLC

Encorafenib Plus Binimetinib Shows ‘Prolonged Efficacy’ in Metastatic NSCLC

SOHO-01 and FURTHER: Dr. Xiuning Le Discusses IASLC Presidential Symposium Presentations

SOHO-01 and FURTHER: Dr. Xiuning Le Discusses IASLC Presidential Symposium Presentations

Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients

Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients

Phase II Study of Taletrectinib Shows Clinically Meaningful Overall Response and Favorable Safety in Patients with ROS1+ Non-Small Cell Lung Cancer

Phase II Study of Taletrectinib Shows Clinically Meaningful Overall Response and Favorable Safety in Patients with ROS1+ Non-Small Cell Lung Cancer